drugset
Drugs / lesogaberan
last change Dec 2017 re-read 9 days ago

lesogaberan

also known as AZD3355

Small molecule targets GABBR1, GABBR2 via activation

Developed for
gastroesophageal reflux disease
Investigated by
AstraZeneca · Ministry of Science and Technology, Taiwan · National Taiwan University Hospital

Trials 10

today NCT02818309 · Ph 2 NCT01043185 · Ph 2 NCT01005251 · Ph 2 NCT00863161 · Ph 1 NCT00757419 · Ph 1 NCT00703534 · Ph 2 NCT00688402 · Ph 1 NCT00684190 · Ph 1 NCT00743444 · Ph 2 NCT00394472 · Ph 2
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 14 trials · 1 met primary
Phase 1 NCT00863161 Mar 2009 → Feb 2010 gastroesophageal reflux disease AstraZeneca Completed No outcome recorded
Phase 1 NCT00757419 Sep → Dec 2008 gastroesophageal reflux disease AstraZeneca Completed No outcome recorded
Phase 1 NCT00688402 Apr → Jun 2008 gastroesophageal reflux disease AstraZeneca Completed No outcome recorded
Phase 1 NCT00684190 Mar → Jun 2008 gastroesophageal reflux disease AstraZeneca Completed Met primary
Phase 26 trials · 1 met primary
Phase 2 NCT02818309 Jan 2015 → Nov 2017 gastroesophageal reflux disease National Taiwan University Hospital Unknown No outcome recorded
Phase 2 NCT01043185 Dec 2009 → May 2010 gastroesophageal reflux disease AstraZeneca Completed No outcome recorded
Phase 2 NCT01005251 Oct 2009 → Jul 2010 dyspepsia, gastroesophageal reflux disease AstraZeneca Completed No outcome recorded
Phase 2 NCT00703534 May 2008 → Jan 2009 dyspepsia, gastroesophageal reflux disease AstraZeneca Completed No outcome recorded
Phase 2 NCT00743444 Feb 2007 → Feb 2008 gastroesophageal reflux disease AstraZeneca Completed No outcome recorded
Phase 2 NCT00394472 Nov 2006 → Jun 2007 gastroesophageal reflux disease AstraZeneca Completed Met primary

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 14 sources stand behind the page.

FieldValueCited text
Known as lesogaberan “The γ-aminobutyric acid type B-receptor agonist lesogaberan (AZD3355) has been developed for use in patients with gastroesophageal reflux disease (GERD) symptoms despite proton...” PMID 25407279 ↗ Nov 2014
2

NCT01005251 ↗

NCT02818309 ↗
Known as AZD3355 “Lesogaberan (AZD3355) is a novel γ-aminobutyric acid B-type receptor agonist designed to treat gastro-oesophageal reflux disease (GERD) by inhibiting transient lower...” PMID 22730470 ↗ Jun 2012
8

NCT00757419 ↗

NCT00394472 ↗

NCT00703534 ↗

NCT00863161 ↗

NCT00684190 ↗

NCT00688402 ↗

NCT01043185 ↗

NCT00743444 ↗
Action Activate “a novel gamma-aminobutyric acid type B receptor agonist” PMID 20451523 ↗ May 2010
2

“GABA-B receptor 2 agonist” CHEMBL448343 ↗

“GABA-B receptor 1 agonist” CHEMBL448343 ↗
Modality Small molecule — CHEMBL448343 ↗
Route Oral “150 mg bid, oral, 7 days” NCT00684190 ↗
Target GABBR1 “GABA-B receptor 1 agonist” CHEMBL448343 ↗
Target GABBR2 “GABA-B receptor 2 agonist” CHEMBL448343 ↗